Venous thromboembolism and prostate cancer: what about genetic markers?
Sofia Coelho AbreuValéria TavaresFilipa CarneiroRui MedeirosPublished in: Pharmacogenomics (2021)
Aim & methods: To review the existing literature concerning the relationship between venous thromboembolism (VTE) and prostate cancer (PC) and explore the putative biological and clinical implications of VTE genetic markers on PC patients by screening the PubMed database. Results: Considering the roles of VTE genome-wide association studies-identified genetic determinants in disease development in the general population, these variants might also underlie the susceptibility for PC-related VTE. Therefore, they could help to identify those with a positive benefit-to-harm ratio for thromboprophylaxis approaches during cancer therapy management, thereby improving patient's prognosis. Conclusion: Future studies are mandatory to explore the relationship between VTE and PC and dissect the predictive value of VTE genome-wide association studies-identified genetic determinants in PC patients, given their clinical implications.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- prostate cancer
- genome wide association
- end stage renal disease
- copy number
- newly diagnosed
- ejection fraction
- genome wide
- cancer therapy
- chronic kidney disease
- prognostic factors
- radical prostatectomy
- emergency department
- case report
- atrial fibrillation
- dna methylation